ArticleBlood2006
Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production.
Article in Blood, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01244906 (A Phase II Trial of Post-Transplant Cyclophosphamide and Sirolimus for Graft-versus-host Disease), which is not on this map. Cited by 214 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Trial of Post-Transplant Cyclophosphamide and Sirolimus for Graft-versus-host Disease (GVHD) Prophylaxis Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation
Who cites it
214 citing papers in PubMed, 1 synthesis or guideline pooled it, 497 citations in OpenAlex.
- Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide.International journal of hematology · 2022Pooled it
- Everolimus-based immunosuppression induces alloreactive regulatory T cell expansion combined with loss of alloreactive effector T cells.Frontiers in immunology · 2026Trial
- Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD.Blood advances · 2024Trial
- A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT.Annals of hematology · 2021Trial
- Distinct peripheral blood molecular signature emerges with successful tacrolimus withdrawal in kidney transplant recipients.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020Trial
- Trial
- A phase II/III randomized, multicenter trial of prednisone/sirolimusHaematologica · 2018Trial
- Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Trial
- CD49b, a major marker of regulatory T-cells type 1, predicts the response to antiviral therapy of recurrent hepatitis C after liver transplantation.BioMed research international · 2014Trial
- Effects of rapamycin combined with low dose prednisone in patients with chronic immune thrombocytopenia.Clinical & developmental immunology · 2013Trial
- Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients.Hepatology (Baltimore, Md.) · 2013Trial
- A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation.Haematologica · 2012Trial
- Mesenchymal stromal cells treatment attenuates dry eye in patients with chronic graft-versus-host disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Trial
- Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility.Clinical journal of the American Society of Nephrology : CJASN · 2011Trial
- Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2011Trial
- A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2009Trial
- Posttransplant autoimmune hemolytic anemia and other autoimmune cytopenias are increased in very young infants undergoing unrelated donor umbilical cord blood transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2008Trial
- Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2008Trial
- Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2008Trial
- Anti-CD4 antibody-modulated transplants for GVHD prevention in hematopoietic cell transplantation.Blood · 2026Article
154 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
CD4+CD25+ regulatory T (Treg) cells control immunologic tolerance and antitumor immune responses. Therefore, in vivo modification of Treg function by immunosuppressant drugs has broad implications for transplantation biology, autoimmunity, and vaccination strategies. In vivo bioluminescence imaging demonstrated reduced early proliferation of donor-derived luciferase-labeled conventional T cells in animals treated with Treg cells after major histocompatibility complex mismatch bone marrow transplantation. Combining Treg cells with cyclosporine A (CSA), but not rapamycin (RAPA) or mycophenolate mofetil (MMF), suppressed Treg function assessed by increased T-cell proliferation, graft-versus-host disease (GVHD) severity, and reduced survival. Expansion of Treg and FoxP3 expression within this population was lowest in conjunction with CSA, suggesting that calcineurin-dependent interleukin 2 (IL-2) production is critically required for Treg cells in vivo. The functional defect of Treg cells after CSA exposure could be reversed by exogenous IL-2. Further, the Treg plus RAPA combination preserved graft-versus-tumor (GVT) effector function against leukemia cells. Our data indicate that RAPA and MMF rather than CSA preserve function of Treg cells in pathologic immune responses such as GVHD without weakening the GVT effect.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.